GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NAGE · Jun 30, 2026

Niagen Bioscience, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001386570-26-000043General Corporate

Operating cash generation56thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

9.31% · OPTIONAL · VALID

Revenue growth0thOwn-history percentile · N=12

Evidence method

Yoy · gp.fundamentals.revenue

-4.28% · CORE · VALID

Inventory pressure80thOwn-history percentile · N=15

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

69.30% · OPTIONAL · VALID

Gross margin94thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.gross_margin

64.84% · CORE · VALID

Operating margin56thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.operating_margin

2.35% · CORE · VALID

R&D intensity31thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

5.08% · OPTIONAL · VALID

SBC intensity75thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.78% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible

Period transition

What moved in the state?

Cash Generation Increased

Previous: -3.79%
Current: 9.31%
Delta: 13.10%

Growth Decreased

Previous: 3.26%
Current: -4.28%
Delta: -7.54%

Inventory Pressure Decreased

Previous: 76.30%
Current: 69.30%
Delta: -7.01%

Margin Increased

Previous: 63.47%
Current: 64.84%
Delta: 1.38%

Profitability Decreased

Previous: 5.01%
Current: 2.35%
Delta: -2.66%

R And D Intensity Increased

Previous: 4.71%
Current: 5.08%
Delta: 0.37%

Sbc Intensity Increased

Previous: 5.45%
Current: 5.78%
Delta: 0.33%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2026

Similarity: 80%
Compared: 7 dimensions
Coverage: 100%

Growth 9.1 · Margin 20.4 · Profitability 3.8 · Sbc Intensity 21.7 · Cash Generation 36.3 · R And D Intensity 24.6 · Inventory Pressure 5.7

Sep 30, 2025

Similarity: 64%
Compared: 7 dimensions
Coverage: 100%

Growth 77.8 · Margin 1.4 · Profitability 36.1 · Sbc Intensity 36.5 · Cash Generation 5.3 · R And D Intensity 8.2 · Inventory Pressure 18.5

Jun 30, 2024

Similarity: 56%
Compared: 6 dimensions
Coverage: 86%

Margin 43.8 · Profitability 43.8 · Sbc Intensity 62.5 · Cash Generation 18.8 · R And D Intensity 18.8 · Inventory Pressure 55.0

Mar 31, 2025

Similarity: 55%
Compared: 6 dimensions
Coverage: 86%

Margin 2.8 · Profitability 43.8 · Sbc Intensity 65.9 · Cash Generation 43.8 · R And D Intensity 31.3 · Inventory Pressure 52.7

Research Graph

Related governed research

Analogous To · NAGE state analogue 2 →Analogous To · NAGE state analogue 3 →Analogous To · NAGE state analogue 1 →Compared To · Medicinal Chemicals & Botanical Products peers →Analogous To · NAGE state analogue 4 →Has State · Niagen Bioscience, Inc. →Transitioned To · NAGE Fundamental State →Transitioned To · NAGE CASH_GENERATION_INCREASED →Transitioned To · NAGE GROWTH_DECREASED →Transitioned To · NAGE INVENTORY_PRESSURE_DECREASED →Transitioned To · NAGE MARGIN_INCREASED →Transitioned To · NAGE PROFITABILITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.